Welcome to our dedicated page for ACLARION SEC filings (Ticker: ACONW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aclarion, Inc. (ACON, ACONW) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed emerging growth company. These filings document key corporate, financial, and governance events as Aclarion advances its Nociscan SaaS platform for chronic low back pain diagnostics.
Through this page, readers can review current reports on Form 8-K, where Aclarion reports material events such as executive transitions, employment agreements, annual meeting results, and capital structure actions. Recent 8-Ks describe the retirement of a prior Chief Financial Officer, the appointment of a new Chief Financial Officer under a detailed employment agreement that includes salary, bonus eligibility, equity incentives, and severance provisions, and voting outcomes from the company’s annual meeting, including director elections and approval of a reverse stock split.
In addition to 8-Ks, investors typically use this section to locate Aclarion’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain audited and interim financial statements, risk factor discussions, and management’s analysis of the business. For Aclarion, these periodic reports provide context on its commercialization of Nociscan, revenue from Nociscan report delivery, and its status as an emerging growth company.
This page also surfaces insider transaction filings on Form 4 and other ownership disclosures when available, allowing users to monitor equity awards and trading activity by directors and officers. Stock Titan enhances the raw EDGAR data with AI-powered summaries that explain the practical meaning of lengthy filings, highlight key terms in employment agreements and corporate actions, and help readers quickly understand how each filing relates to Aclarion’s diagnostic imaging and spine care business.
Filings are updated as they are posted to EDGAR, giving investors, analysts, and interested clinicians a structured view of Aclarion’s regulatory history and corporate developments over time.
Gregory A. Gould, Chief Financial Officer of Aclarion, Inc. (ticker shown as ACON), reported an option grant on a Form 4 filed 09/03/2025 for a transaction dated 09/02/2025. The filing shows an award of 17,000 stock options with an exercise price of $7.15. The options are reported as directly held and the underlying common stock amount is 17,000 shares.
The filing explains the vesting schedule: 25% vests on September 2, 2026, and the remaining 75% vests in 36 equal monthly installments thereafter. The derivative shows an expiration or related date of 09/02/2035 in the table and the reporting person signed the form on 09/03/2025.
Gregory A. Gould, who is listed as an officer (CFO) and director of Aclarion, Inc. (ACON), filed an initial Form 3 reporting event dated 09/02/2025. The filing states that Mr. Gould does not beneficially own any securities of the issuer at the time of the report. The form provides his business address in Broomfield, Colorado, and is signed 09/03/2025.
Aclarion, Inc. disclosed the appointment of Gregory A. Gould as Chief Financial Officer with an employment agreement effective
Aclarion, Inc. reported results for the quarter ended June 30, 2025. Cash and cash equivalents were $12,850,657 (including $11,949,908 in money market funds), which management believes funds operations into the third quarter of 2026. Revenue grew to $19,319 in Q2 2025 (up 76% year-over-year) and $38,309 for the six months (up 82%), driven by increased NOCISCAN report volume in the U.K. Q2 gross profit was $5,140, but operating expenses rose to $1.74 million, producing a Q2 net loss of $1.60 million and a six-month net loss of $3.64 million. In H1 2025 the company raised approximately $20.1 million via a public unit offering, two registered direct offerings and warrant exercises. Corporate actions included two 2025 reverse stock splits and the $1,213,590 redemption of Series B preferred stock. The company recorded a $687,500 settlement in March 2025. Readers should consult the full notes for detailed terms of warrants, preferred conversions, and cash assumptions.
FAQ
What is the current stock price of ACLARION (ACONW)?
